Keeps Biopharma, Which Has Expanded Its Pharma and Biotech Business, Surpasses Last Year's Revenue in Nine Months
- Input
- 2026-11-16 16:18:08
- Updated
- 2026-11-16 16:18:08

[Financial News] Keeps Biopharma surpassed 200 billion won in cumulative revenue through the third quarter, buoyed by a series of mergers and acquisitions (M&A) and the expansion of its pharma and biotech business.
After surpassing last year's full-year revenue in just nine months, the contribution of acquired subsidiaries is also beginning to come through in earnest, led by the oncology business.
According to the Financial Supervisory Service's Data Analysis, Retrieval and Transfer System (DART) on the 16th, Keeps Biopharma's consolidated revenue for the first three quarters of this year was 202.8 billion won, up 62% from the same period a year earlier. That already exceeded last year's full-year revenue of 170.1 billion won. Third-quarter revenue also rose 67% year on year to 68.4 billion won.
The pharma and biotech business is a key pillar of the company's growth. Cumulative revenue from this segment surged 92% year on year to 69.3 billion won. Third-quarter revenue rose 127% to 27.4 billion won. Its share of total quarterly revenue also increased from 30% last year to 40% this year.
In particular, the results of M&A deals are becoming visible, especially in the oncology business.
Bigthink, a subsidiary specializing in oncology, saw cumulative revenue grow roughly threefold year on year to 9.6 billion won and turned profitable, posting an operating profit of 300 million won. Elpis Pharm, an oncology drug distributor acquired this year, was included in the results from the second quarter and posted cumulative revenue of 23.5 billion won and operating profit of 700 million won.
As the company expanded its business, R&D and business expansion costs weighed on results, resulting in a cumulative operating loss of 8 billion won and a net loss for the period of 8.6 billion won. However, the acquired subsidiaries have begun generating profits, laying the groundwork for improved consolidated profitability going forward, according to an assessment.
A source in the pharma and biotech industry said, "What stands out is that Keeps Biopharma is strengthening both the distribution infrastructure for its oncology business and its revenue-generating structure, rather than simply increasing sales," and assessed that "as the contribution from acquired subsidiaries grows, it could also help secure the funding needed for new drug development and improve profitability."
Keeps Biopharma CEO Kim Ha-yong emphasized, "Thanks to the expansion of our pharma and biotech business and the effects of M&A, we surpassed last year's full-year revenue in just nine months," adding, "Going forward, we will focus on securing profitability commensurate with our expanded scale."
Kim Ha-yong added that "starting in the first half of 2027, we may be able to announce concrete results, including interim results from a UK combination trial of the next-generation ovarian cancer treatment idetrexed and additional patents for the oral platform Oraloid."
[email protected] Kim Gyeong-a Reporter